Publications by Date
-
NN106: "Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial"
Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trialNeurooncology Advances.2021 December 24;4(1)doi: 10.1093/noajnl/vdab1.PubMed: PMID:35088051 -
NN103 Primary Manuscript: "Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study"
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG StudyNeurology.2021 December 2;doi: 10.1212/WNL.00000000.PubMed: PMID: 34857535 -
Virtual coordinator and site training and reorganization of a multisite consortium upon grant renewal: Challenges of the NeuroNEXT network
Virtual coordinator and site training and reorganization of a multisite consortium upon grant renewal: Challenges of the NeuroNEXT networkContemporary Clinical Trials Communications.2021 September;Volume 23(eCollection 2021 Sep)https://doi.org/10.1016/j.PubMed: PMC8340117 -
NN109: "Safety and Efficacy of N-Acetylmannosamine (ManNAc) in Patients with GNE Myopathy: An Open-Label Phase 2 Study"
Safety and Efficacy of N-Acetylmannosamine (ManNAc) in Patients with GNE Myopathy: An Open-Label Phase 2 StudyGenetics in Medicine.2021 July 13;23(11)2067-2075.PubMed: PMID: 34257421 -
NN102 Manuscript: "Influence of equipment changes on MRI measures of brain atrophy and brain microstructure in a placebo-controlled trial of ibudilast in progressive multiple sclerosis"
Influence of equipment changes on MRI measures of brain atrophy and brain microstructure in a placebo-controlled trial of ibudilast in progressive multiple sclerosisMultiple Sclerosis Journal - Experimental, Translational and Clinical.2021 May 18;7(2)1-10.PubMed: PMC8138298 -
NN102 Manuscript: "Response to Ibudilast treatment according to progressive multiple sclerosis disease phenotype'"
Response to Ibudilast treatment according to progressive multiple sclerosis disease phenotypeAnnals of Clinical & Translational Neurology.2021 January;8(1)111-118.PubMed: PMC7818089 -
NN102 Manuscript: "Effects of Ibudilast on MRI measures in the Phase 2 SPRINT-MS Study"
Effects of Ibudilast on MRI measures in the Phase 2 SPRINT-MS StudyNeurology.2021 January ;96(4)e491-e500.PubMed: PMC7905793 -
NN102 OCT Manuscript: "Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis"
Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosisMultiple Sclerosis Journal.2020 Oct 15;PubMed: 33054533 -
NeuroNEXT Infrastructure Paper: "Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials"
Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical TrialsJAMA Neurology.2020 June;77(6)755-763.PubMed: PMC7483960 -
NN105 Primary Manuscript: "Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial"
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical TrialJournal of Clinical Medicine.2020;9(3682)1-14.PubMed: PMC7696926 -
NN104 Primary Endpoint Publication
Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant Human Activated Protein C, in Combination with Tissue Plasminogen Activ...Annals of Neurology.2019;85125-136. -
NN101 Recruitment and Retention Manuscript: "Recruitment & Retention Program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA! Contemporary Clinical Trials Communication"
Recruitment & Retention Program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!Contemporary Clinical Trials Communications.2018 September;11113-119.PubMed: PMC6072892 -
NN102 Primary Endpoint Publication
Phase 2 Trial of Ibudilast in Progressive Multiple SclerosisNew England Journal of Medicine.2018 Aug 30;379(9)846-855.PubMed: PMC6172944 -
NN101: "Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study"
Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker StudyJournal of Neuromuscular Diseases.2018;5(4)509-521.PubMed: 30223401 -
Editorial accompanying NN101 SMA primary results publication
NeuroNEXT is at your serviceAnnals of Neurology.2017 Dec.;82(6)857-858. -
NN101 Primary Manuscript: "Natural History of Infantile-Onset Spinal Muscular Atrophy"
Natural History of Infantile-Onset Spinal Muscular AtrophyAnnals of Neurology.2017 Dec.;82(6)883-891.PubMed: PMC5776712 -
NN104 Paper, "Selecting patients for intraarterial therapy in the context of a clinical trial for neuroprotection"
Selecting patients for intraarterial therapy in the context of a clinical trial for neuroprotection.Stroke.2016;47(12)2979-2985.PubMed: PMC5134840 -
NN102 Paper, "Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis"
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.Contemporary Clinical Trials.2016;50166-177.PubMed: PMC5035622 -
NN101 Paper, "Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study"
Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study.Annals of Clinical and Translational Neurology.2016;3(2)132-45.PubMed: PMC4748311 -
You May Have Worked on More Adaptive Designs Than You Think
You May Have Worked on More Adaptive Designs Than You ThinkStroke.2015;46(2)e26-28.PubMed: PMC4308449 -
Central Institutional Review Board Review for an Academic Trial Network
Central Institutional Review Board Review for an Academic Trial NetworkAcademic Medicine.2015;90(3)321-3.PubMed: PMC4859204 -
Ullman editorial in "Annals of Neurology" highlighting NeuroNEXT
A Burst of speed for neurological researchAnnals of Neurology.2013;74(2)A7-8. -
Adaptive trial designs: A review of barriers and opportunities
Adaptive trial designs: A review of barriers and opportunitiesTrials.2012;13145.PubMed: PMC3519822 -
NeuroNEXT: accelerating drug development in Neurology
NeuroNEXT: accelerating drug development in NeurologyLancet Neurology.2012;11(2)119. -
Trial Networks Move Beyond Single-Disease Strategies
Trial Networks Move Beyond Single-Disease Strategies.Nat Med.2011;6(17(12))1525.